diethyl 6-bromo-3-formylphthalate | 1082059-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl 6-bromo-3-formylphthalate
• 英文别名: Diethyl 3-bromo-6-formylbenzene-1,2-dicarboxylate
• CAS: 1082059-16-2
• 化学式: C₁₃H₁₃BrO₅
• 分子量: 329.147
• InChiKey: QQBZBFKHCRBUHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  吡咯 、 diethyl 6-bromo-3-formylphthalate 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 生成 5,10,15,20-tetrakis[4-bromo-2,3-bis(ethoxycarbonyl)phenyl]-21H,23H-porphine
  参考文献：
  名称：

  The porphyrin–fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect

  摘要：

  This is a first case ever reported on the fullerene-based low toxic nanocationite particles (porphyrin adducts of cyclohexyl fullerene-C-60) designed for targeted delivery of the paramagnetic magnesium stable isotope to the heart muscle providing a sharp clinical effect close to about 80% recovery of the tissue hypoxia symptoms in less than 24 h after a single injection (0.03-0.1 LD50). A whole principle of this therapy is novel: Mg-25(2+)-magnetic isotope effect selectively stimulates the ATP overproduction in the oxygen-depleted cells due to Mg-25(2+) released by the nanoparticles. Being membranotropic cationites, these "smart nanoparticles" release the overactivating paramagnetic cations only in response to the metabolic acidic shift. The resulting positive changes in the heart cell energy metabolism may help to prevent and/or treat the local myocardial hypoxic disorders and, hence, protect the heart muscle from a serious damage in a vast variety of the hypoxia-caused clinical situations including both doxorubicin and 1-methylnicotineamide cardiotoxic side effects. Both pharmacokinetics and pharmacodynamics of the drug proposed make it suitable for safe and efficient administration in either single or multi-injection (acute or chronic) therapeutic schemes. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.07.030
• 作为产物：
  描述：

  diethyl 3-formyl-6-(trimethylsilyl)phthalate 在 N-溴代丁二酰亚胺(NBS) 、 四丁基氟化铵 作用下， 生成 diethyl 6-bromo-3-formylphthalate
  参考文献：
  名称：

  The porphyrin–fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect

  摘要：

  This is a first case ever reported on the fullerene-based low toxic nanocationite particles (porphyrin adducts of cyclohexyl fullerene-C-60) designed for targeted delivery of the paramagnetic magnesium stable isotope to the heart muscle providing a sharp clinical effect close to about 80% recovery of the tissue hypoxia symptoms in less than 24 h after a single injection (0.03-0.1 LD50). A whole principle of this therapy is novel: Mg-25(2+)-magnetic isotope effect selectively stimulates the ATP overproduction in the oxygen-depleted cells due to Mg-25(2+) released by the nanoparticles. Being membranotropic cationites, these "smart nanoparticles" release the overactivating paramagnetic cations only in response to the metabolic acidic shift. The resulting positive changes in the heart cell energy metabolism may help to prevent and/or treat the local myocardial hypoxic disorders and, hence, protect the heart muscle from a serious damage in a vast variety of the hypoxia-caused clinical situations including both doxorubicin and 1-methylnicotineamide cardiotoxic side effects. Both pharmacokinetics and pharmacodynamics of the drug proposed make it suitable for safe and efficient administration in either single or multi-injection (acute or chronic) therapeutic schemes. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.07.030

文献信息

• EP1992627A1
  申请人：——

  公开号：EP1992627A1

  公开（公告）日：2008-11-19
• EP1992339A1
  申请人：——

  公开号：EP1992339A1

  公开（公告）日：2008-11-19
• USE OF A MAGNESIUM ISOTOPE FOR TREATING HYPOXIA AND A MEDICAMENT COMPRISING THE SAME
  申请人：Sarkar Saeed

  公开号：US20080317876A1

  公开（公告）日：2008-12-25

  The present invention describes the use of the magnetic magnesium isotope 25 Mg 2+ for the manufacture of a medicament for treating hypoxia. Furthermore, the present invention provides a medicament for treating hypoxia comprising the magnetic magnesium isotope 25 Mg 2+ and a porphylleren compound according to formula (I) wherein the residues A 1 , A 2 , A 3 , and A 4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R′ and R″ independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable of complexing with pyrrole nitrogen atom and L is a linking group and B is a fullerene residue.
• NEW WATER SOLUBLE PORPHYLLEREN COMPOUNDS
  申请人：Sarkar Saeed

  公开号：US20080319187A1

  公开（公告）日：2008-12-25

  Provides is a porphylleren compound (and methods for preparation thereof) according to formula (I) where the residues A 1 , A 2 A 3 , and A 4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R′ and R″ independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable of complexing with pyrrole nitrogen atom and L is a linking group and B is a fullerene residue.
• US7879996B2
  申请人：——

  公开号：US7879996B2

  公开（公告）日：2011-02-01